Brokerages forecast that Strongbridge Biopharma plc (NASDAQ:SBBP) will report sales of $5.48 million for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Strongbridge Biopharma’s earnings, with the highest sales estimate coming in at $5.99 million and the lowest estimate coming in at $4.90 million. Strongbridge Biopharma reported sales of $2.53 million during the same quarter last year, which indicates a positive year-over-year growth rate of 116.6%. The company is expected to announce its next earnings results on Tuesday, November 13th.

On average, analysts expect that Strongbridge Biopharma will report full year sales of $20.30 million for the current fiscal year, with estimates ranging from $18.65 million to $21.81 million. For the next year, analysts expect that the business will post sales of $45.06 million, with estimates ranging from $27.85 million to $59.75 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Strongbridge Biopharma.

Strongbridge Biopharma (NASDAQ:SBBP) last announced its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.41. The firm had revenue of $4.30 million during the quarter, compared to the consensus estimate of $4.53 million.

Several brokerages recently commented on SBBP. HC Wainwright set a $18.00 target price on shares of Strongbridge Biopharma and gave the stock a “buy” rating in a report on Thursday, August 9th. BidaskClub raised shares of Strongbridge Biopharma from a “sell” rating to a “hold” rating in a report on Tuesday, June 19th. Cantor Fitzgerald set a $17.00 target price on shares of Strongbridge Biopharma and gave the stock a “buy” rating in a report on Wednesday, August 8th. JMP Securities lifted their target price on shares of Strongbridge Biopharma from $10.00 to $16.00 and gave the stock a “market outperform” rating in a report on Thursday, August 9th. Finally, Janney Montgomery Scott lifted their target price on shares of Strongbridge Biopharma to $16.00 and gave the stock a “buy” rating in a report on Wednesday, August 8th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $14.75.

Shares of SBBP remained flat at $$5.00 during midday trading on Monday. 610,831 shares of the stock were exchanged, compared to its average volume of 416,233. Strongbridge Biopharma has a 52 week low of $3.85 and a 52 week high of $9.25. The company has a market cap of $226.54 million, a P/E ratio of -3.45 and a beta of 0.80. The company has a current ratio of 6.46, a quick ratio of 6.38 and a debt-to-equity ratio of 8.76.

In related news, major shareholder Associates L.L.C. Cdk bought 11,200 shares of Strongbridge Biopharma stock in a transaction that occurred on Monday, July 16th. The stock was acquired at an average price of $4.97 per share, with a total value of $55,664.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders have purchased a total of 910,795 shares of company stock valued at $4,430,231 in the last ninety days. 4.20% of the stock is currently owned by insiders.

Several hedge funds have recently made changes to their positions in SBBP. Laurion Capital Management LP bought a new stake in shares of Strongbridge Biopharma during the 2nd quarter worth about $101,000. Dynamic Technology Lab Private Ltd bought a new stake in Strongbridge Biopharma in the 2nd quarter valued at about $110,000. Cubist Systematic Strategies LLC bought a new stake in Strongbridge Biopharma in the 2nd quarter valued at about $130,000. Jane Street Group LLC bought a new stake in Strongbridge Biopharma in the 2nd quarter valued at about $154,000. Finally, Citadel Advisors LLC bought a new stake in Strongbridge Biopharma in the 1st quarter valued at about $166,000. 66.89% of the stock is owned by institutional investors and hedge funds.

About Strongbridge Biopharma

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency in the United States and Canada.

Read More: How do investors use RSI to grade stocks?

Get a free copy of the Zacks research report on Strongbridge Biopharma (SBBP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.